RxDoctor Payments Data

Alexander Hajduczok

Tulsa, OKNPI 1447742101

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.1%), grants and food and beverage — rather than concentrated in one kind of arrangement. Cvrx, Inc. accounts for 69.8% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $22,502, more than ten times the $139 reported in 2021.

$41,809in general payments, 2019–2025

Across 115 payments — averaging $363.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$29K
  • Abbott$8K
  • Edwards Lifesciences$1K
  • Impulse Dynamics (USA) Inc.$1K
  • Actelion Pharmaceuticals US, Inc.$297
  • Amgen$250
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$23,87557%
  • Grants$6,75016%
  • Travel & lodging$4,92912%
  • Food & beverage$6,25515%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium17$212
Warfarin Sodium11$114
Lisinopril15$50

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →